An economic survey of the emerging tissue engineering industry.
The contemporary scope of worldwide tissue engineering research and development was estimated by totaling the relevant annual spending and other economic parameters of firms involved the field. Operating expenses allocated to tissue engineering in 1997 exceed $450 million and fund the activities of nearly 2,500 scientists and support personnel. Growth rate is 22.5% per annum. Most activity is centered in the United States. Government spending in this field represents <10% of the total. The aggregate capital value of start-ups that have gone public was approximately $1.7 billion as of January 1, 1998; total capital value of all firms and business units in the field was estimated to be roughly $3.5 billion. The level of investment and valuation represents a remarkable act of faith in the future of a technology yet to produce its first significant revenue-generating product.
Lysaght
M J
MJ
Department of Molecular Pharmacology, Physiology, and Biotechnology, Division of Biology and Medicine, Brown University, Providence, Rhode Island, USA.
Nguy
N A
NA
Sullivan
K
K
D001187:Artificial Organs / Q000191:economics; D001698:Biomedical Engineering / Q000191:economics* / Q000458:organization & administration; D001705:Bioprosthesis / Q000191:economics; D004467:Economics / Q000706:statistics & numerical data; D005380:Financing, Government / Q000706:statistics & numerical data; D005381:Financing, Organized / Q000706:statistics & numerical data; D006801:Humans; D007449:Investments / Q000706:statistics & numerical data; D012109:Research Support as Topic; D014481:United States; D000078329:Workforce